1. Home
  2. AROW vs ERAS Comparison

AROW vs ERAS Comparison

Compare AROW & ERAS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • AROW
  • ERAS
  • Stock Information
  • Founded
  • AROW 1851
  • ERAS 2018
  • Country
  • AROW United States
  • ERAS United States
  • Employees
  • AROW N/A
  • ERAS N/A
  • Industry
  • AROW Major Banks
  • ERAS Biotechnology: Pharmaceutical Preparations
  • Sector
  • AROW Finance
  • ERAS Health Care
  • Exchange
  • AROW Nasdaq
  • ERAS Nasdaq
  • Market Cap
  • AROW 442.9M
  • ERAS 439.7M
  • IPO Year
  • AROW N/A
  • ERAS 2021
  • Fundamental
  • Price
  • AROW $30.99
  • ERAS $2.20
  • Analyst Decision
  • AROW Hold
  • ERAS Buy
  • Analyst Count
  • AROW 1
  • ERAS 6
  • Target Price
  • AROW $28.00
  • ERAS $3.67
  • AVG Volume (30 Days)
  • AROW 37.4K
  • ERAS 1.2M
  • Earning Date
  • AROW 10-30-2025
  • ERAS 11-07-2025
  • Dividend Yield
  • AROW 3.84%
  • ERAS N/A
  • EPS Growth
  • AROW 5.41
  • ERAS N/A
  • EPS
  • AROW 2.07
  • ERAS N/A
  • Revenue
  • AROW $146,817,000.00
  • ERAS N/A
  • Revenue This Year
  • AROW $22.74
  • ERAS N/A
  • Revenue Next Year
  • AROW $6.91
  • ERAS N/A
  • P/E Ratio
  • AROW $15.00
  • ERAS N/A
  • Revenue Growth
  • AROW 7.84
  • ERAS N/A
  • 52 Week Low
  • AROW $22.72
  • ERAS $1.01
  • 52 Week High
  • AROW $34.63
  • ERAS $3.31
  • Technical
  • Relative Strength Index (RSI)
  • AROW 71.69
  • ERAS 46.03
  • Support Level
  • AROW $26.17
  • ERAS $2.34
  • Resistance Level
  • AROW $27.80
  • ERAS $2.54
  • Average True Range (ATR)
  • AROW 0.80
  • ERAS 0.16
  • MACD
  • AROW 0.49
  • ERAS -0.04
  • Stochastic Oscillator
  • AROW 91.48
  • ERAS 6.67

About AROW Arrow Financial Corporation

Arrow Financial Corp is a holding company. It provides various advisory and administrative services and coordinates the general policies and operations of the banks. It provides financial products, including online and mobile banking, mortgages, commercial loans, investments, and others. The company also provides lending services including commercial and industrial lending to small and mid-sized companies; mortgage lending for residential and commercial properties; and consumer installment and home equity financing. The key source of company's revenue is interest income, fees, commission earned through its subsidiaries.

About ERAS Erasca Inc.

Erasca Inc is a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company's product pipeline includes; Naporafenib, a pan-RAF inhibitor with first-in-class potential in NRASm melanoma, RAS Q61X tissue agnostic solid tumors, and other RAS/MAPK pathway-driven tumors, and ERAS-007 (oral ERK1/2 inhibitor) and ERAS-601 (oral SHP2 inhibitor), which target downstream and upstream nodes, respectively, of the RAS/MAPK pathway.

Share on Social Networks: